BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/24/2026 6:11:15 AM | Browse: 2 | Download: 0
 |
Received |
|
2025-11-13 06:10 |
|
Peer-Review Started |
|
2025-11-13 06:10 |
|
First Decision by Editorial Office Director |
|
2025-11-21 09:55 |
|
Return for Revision |
|
2025-11-21 09:55 |
|
Revised |
|
2025-11-21 23:54 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-12-23 02:34 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-12-23 03:32 |
|
Articles in Press |
|
2025-12-23 03:32 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-14 00:45 |
|
Publish the Manuscript Online |
|
2026-07-24 06:11 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Editorial |
| Article Title |
Emergence of human epidermal growth factor receptor 2 as key biomarker and therapeutic target in advanced urothelial carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Nabil Ismaili |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Nabil Ismaili, Associate Professor, Chief Physician, Director, MD, Department of Medical Oncology, Mohammed VI Faculty of Medicine, Mohammed VI University of Sciences and Health (UM6SS), Mohammed VI Foundation of Sciences and Health (FM6SS), Boulevard Mohamed Taïeb Naciri, Commune Hay Hassani, Casablanca 82403, Morocco. ismailinabil@yahoo.fr |
| Key Words |
Human epidermal growth factor receptor 2; Urothelial carcinoma; Antibody-drug conjugate; Disitamab vedotin; Biomarker |
| Core Tip |
This commentary highlights the critical findings of Huang et al., which establish a strong link between HER2 overexpression and high-grade upper tract urothelial carcinoma (UTUC), revealing a distinct biological profile compared to bladder cancer. These results gain immediate clinical relevance with the recent paradigm-shifting data from the phase 3 RC48-C016 trial. The combination of the anti-HER2 antibody-drug conjugate disitamab vedotin and the anti-PD-1 toripalimab has demonstrated superior efficacy over standard chemotherapy in first-line HER2-expressing metastatic urothelial carcinoma, nearly doubling progression-free survival and significantly improving overall survival with a better safety profile. Given that nearly half of UTUC tumors are HER2-positive, these findings urgently position a substantial patient subset as potential candidates for this novel, biomarker-driven therapy, heralding a new era in urothelial carcinoma treatment. |
| Publish Date |
2026-07-24 06:11 |
| Citation |
Ismaili N. Emergence of human epidermal growth factor receptor 2 as key biomarker and therapeutic target in advanced urothelial carcinoma. World J Clin Oncol 2026; 17(7): 116520
|
| URL |
https://www.wjgnet.com/2218-4333/full/v17/i7/116520.htm |
| DOI |
https://doi.org/10.5306/wjco.116520 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
